We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
- Authors
Visentin, Andrea; Imbergamo, Silvia; Scomazzon, Edoardo; Pravato, Stefano; Frezzato, Federica; Bonaldi, Laura; Pizzi, Marco; Vio, Stefania; Gregianin, Michele; Burei, Marta; Facco, Monica; Semenzato, Gianpietro; Piazza, Francesco; Trentin, Livio
- Abstract
The article discusses the Richter syndrome (RS) which is the transformation of chronic lymphocytic leukaemia (CLL) into an aggressive lymphoma like the diffuse large B cell lymphoma which is the most common. It states that B-cell receptor (BCR) kinase inhibitors, idelalisib and ibrutinib are active and effective treatment in RS.
- Publication
British Journal of Haematology, 2019, Vol 185, Issue 1, p193
- ISSN
0007-1048
- Publication type
Academic Journal
- DOI
10.1111/bjh.15440